Clinical Trials Browser

Imatinib Mesylate × Other hematologic neoplasm × Clear all

NCT00070499 2026-05-26

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Phase 2 Active not recruiting

406 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-05-11

Asciminib Roll-over Study

Phase 4 Recruiting

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04307576 2026-05-05

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03007147 2026-05-04

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04626024 2026-05-04

TOKIN

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Phase 2 Completed

104 enrolled 33 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT07413263 2026-02-18

Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

Not yet recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Phase 2 Active not recruiting

81 enrolled 20 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT02881086 2025-12-16

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Phase 3 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

245 enrolled 15 charts 1 FDA

LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT04070443 2025-11-18

TIPI

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01316250 2025-10-02

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Phase NA Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07022743 2025-09-05

Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00015847 2025-08-22

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2 Terminated

25 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07091019 2025-07-29

ASC4REAL-2

Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT00476190 2025-06-12

ALL Adult Consortium Trial: Adult ALL Trial

Phase 2 Completed

112 enrolled 17 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01860456 2025-06-05

TIKlet

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT05413915 2025-05-21

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05071482 2025-05-01

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Phase 4 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01085617 2025-03-30

UKALL14

OtherOther hematologic neoplasm

Leukemia, Mucositis

NCT03844360 2025-03-30

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT05282108 2025-03-26

CARCML

MyeloidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT01804985 2025-03-14

DESTINY

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03906292 2025-03-10

CMLXI

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04722848 2025-01-23

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03722420 2024-10-28

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Phase 3 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT06646978 2024-10-17

K2SPIRIT

Enrolling by invitation

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02326311 2024-08-13

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Phase 3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02001818 2024-08-06

PInNACLe

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1 Completed

326 enrolled 1 FDA

MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06175702 2023-12-19

LALPh2022

Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03193281 2023-11-29

KISS

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05286528 2023-10-27

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

1,484 enrolled 6 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01593254 2023-06-22

DASCERN

Phase 2 Completed

262 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT00002514 2023-06-18

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Phase 3 Completed

Other hematologic neoplasm

Leukemia

NCT00287105 2023-05-24

ESPHALL

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00558961 2023-03-27

GL-CLB-001

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02269267 2023-03-03

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Phase 2 Completed

173 enrolled 14 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03885830 2023-01-11

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01005914 2023-01-06

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2 Terminated

11 enrolled 6 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01475110 2022-10-25

CML0609

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01319981 2022-09-27

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Phase 2 Completed

31 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03023046 2022-07-13

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Completed

54 enrolled 13 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma